GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (STU:2I3) » Definitions » Cyclically Adjusted PS Ratio

Champions Oncology (STU:2I3) Cyclically Adjusted PS Ratio : 1.83 (As of Jun. 02, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Champions Oncology Cyclically Adjusted PS Ratio?

As of today (2025-06-02), Champions Oncology's current share price is €5.15. Champions Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2025 was €2.81. Champions Oncology's Cyclically Adjusted PS Ratio for today is 1.83.

The historical rank and industry rank for Champions Oncology's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:2I3' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.84   Med: 2.76   Max: 9.1
Current: 1.92

During the past years, Champions Oncology's highest Cyclically Adjusted PS Ratio was 9.10. The lowest was 0.84. And the median was 2.76.

STU:2I3's Cyclically Adjusted PS Ratio is ranked better than
74.4% of 496 companies
in the Biotechnology industry
Industry Median: 5.54 vs STU:2I3: 1.92

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Champions Oncology's adjusted revenue per share data for the three months ended in Jan. 2025 was €1.146. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.81 for the trailing ten years ended in Jan. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Champions Oncology Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Champions Oncology's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Cyclically Adjusted PS Ratio Chart

Champions Oncology Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.81 5.12 3.21 1.85 1.71

Champions Oncology Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.11 1.71 1.65 1.32 3.59

Competitive Comparison of Champions Oncology's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Champions Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Cyclically Adjusted PS Ratio falls into.


;
;

Champions Oncology Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Champions Oncology's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=5.15/2.81
=1.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2025 is calculated as:

For example, Champions Oncology's adjusted Revenue per Share data for the three months ended in Jan. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=1.146/134.0288*134.0288
=1.146

Current CPI (Jan. 2025) = 134.0288.

Champions Oncology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201504 0.337 99.824 0.452
201507 0.295 100.691 0.393
201510 0.304 100.346 0.406
201601 0.270 99.957 0.362
201604 0.288 100.947 0.382
201607 0.338 101.524 0.446
201610 0.369 101.988 0.485
201701 0.306 102.456 0.400
201704 0.281 103.167 0.365
201707 0.397 103.278 0.515
201710 0.403 104.070 0.519
201801 0.379 104.578 0.486
201804 0.365 105.708 0.463
201807 0.422 106.324 0.532
201810 0.415 106.695 0.521
201901 0.489 106.200 0.617
201904 0.469 107.818 0.583
201907 0.517 108.250 0.640
201910 0.532 108.577 0.657
202001 0.594 108.841 0.731
202004 0.632 108.173 0.783
202007 0.584 109.318 0.716
202010 0.571 109.861 0.697
202101 0.612 110.364 0.743
202104 0.598 112.673 0.711
202107 0.710 115.183 0.826
202110 0.698 116.696 0.802
202201 0.811 118.619 0.916
202204 0.845 121.978 0.928
202207 0.999 125.002 1.071
202210 1.071 125.734 1.142
202301 0.874 126.223 0.928
202304 0.879 127.992 0.920
202307 0.841 128.974 0.874
202310 0.812 129.810 0.838
202401 0.812 130.124 0.836
202404 0.961 132.289 0.974
202407 0.923 132.708 0.932
202410 0.883 133.182 0.889
202501 1.146 134.029 1.146

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Champions Oncology  (STU:2I3) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Champions Oncology Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology Business Description

Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Champions Oncology Headlines

No Headlines